Does ENZALUTAMIDE Cause Neoplasm malignant? 113 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 113 reports of Neoplasm malignant have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.2% of all adverse event reports for ENZALUTAMIDE.
113
Reports of Neoplasm malignant with ENZALUTAMIDE
0.2%
of all ENZALUTAMIDE reports
51
Deaths
26
Hospitalizations
How Dangerous Is Neoplasm malignant From ENZALUTAMIDE?
Of the 113 reports, 51 (45.1%) resulted in death, 26 (23.0%) required hospitalization, and 3 (2.7%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 113 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which ENZALUTAMIDE Alternatives Have Lower Neoplasm malignant Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE